

**EXAMPLE OF AN OVARIAN NEOPLASM USING PROPOSED TEMPLATE**

- Case: High-grade serous carcinoma of right ovary primary
  - Total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, regional lymphadenectomy (pelvic and para-aortic lymph nodes), multiple peritoneal biopsies, removal of portion of small intestine
  - Tumor measures 9.0 x 8.3 x 6.6 cm
  - Tumor involves right ovary (surface+), right fallopian tube, uterine serosa, omentum (omental cake), 1 (of 11) pelvic lymph nodes, 0 (of 4) para-aortic lymph nodes, right cul-de-sac, small intestine serosa
  - Negative LVI
  - Positive cytology
  - Hormone receptors: ER positive (50%, variable), PR positive (10%, variable)

**OVARIAN NEOPLASM**

1. **Specimen(s):** Uterus, cervix, bilateral fallopian tubes, bilateral ovaries, omentum, peritoneal biopsies (as specified in gross), portion of small intestine
2. **Procedure(s):** Total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, peritoneal biopsies, segmental excision of small intestine, regional lymphadenectomy (as specified)
3. **Regional Lymph Node Sampling:** Performed
4. **Specimen Integrity:** Intact
5. **Primary Tumor Site:** Right ovary
6. **Tumor Size:**
  - a. Greatest dimension: 9.0 cm
  - b. Total dimensions: 9.0 x 8.3 x 6.6 cm
7. **Histologic Type:** High-grade serous carcinoma
8. **Histologic Grade:** High-grade
9. **Ovarian Stromal Invasion:** Present
10. **Lymph-Vascular Space Invasion:** Absent
11. **Serosal Surface Involvement:** Present; right ovary
12. **Implants/Other Sites Involved:** Present; uterine serosa, omentum, right cul-de-sac, small intestine serosa
13. **Regional Lymph Nodes:** Positive; 1/15; extranodal extension absent
14. **Cytology:** Positive (CN-XX-XXXXX)
15. **Hormone Receptor Expression (by immunohistochemistry):**
  - a. ER: Positive; 50%, variable
  - b. PR: Positive; 10%, variable
16. **Mismatch Repair (MMR) Protein Expression (by immunohistochemistry):**
  - a. Not performed
17. **Pathologic Staging:** AJCC [pT3c N1]; FIGO [IIIC]

**OVARIAN NEOPLASM TEMPLATE (specific details to be added into SOFT)**

1. **Specimen(s):** *list all specimens removed during case*

2. **Procedure(s):** *select all that apply*
  - a. [Total abdominal hysterectomy]
  - b. [Radical hysterectomy]
  - c. [Supracervical hysterectomy]
  - d. [Bilateral salpingo-oophorectomy]
  - e. [Bilateral oophorectomy]
  - f. [Bilateral salpingectomy]
  - g. [Right salpingo-oophorectomy]
  - h. [Right oophorectomy]
  - i. [Right salpingectomy]
  - j. [Left salpingo-oophorectomy]
  - k. [Left oophorectomy]
  - l. [Left salpingectomy]
  - m. [Omentectomy]
  - n. [Peritoneal biopsies]
  - o. [Peritoneal washings]
  - p. [Other, <SPECIFY>]
3. **Regional Lymph Node Sampling:** *select whether or not lymph nodes were removed*
  - a. [Performed]
  - b. [Not performed]
  - c. [Not applicable]
  - d. [Cannot be determined]
4. **Specimen Integrity:** *document whether intact or received fragmented. This absolutely requires correlation with the operative report*
5. **Primary Tumor Site:** *select all that apply*
  - a. [Right ovary]
  - b. [Left ovary]
  - c. [Bilateral ovaries]
  - d. [Cannot be determined]
6. **Tumor Size:** *provide greatest dimension and total dimensions, if both ovaries equally involved, list separately*
  - a. [Greatest dimension: <SPECIFY>]
  - b. [Total dimensions: <SPECIFY>]
  - c. [Cannot be determined]
7. **Histologic Type:** *select appropriate tumor type*
  - a. [Atypical proliferative/borderline serous tumor]
  - b. [Atypical proliferative/borderline serous tumor with micropapillary features]
  - c. [Atypical proliferative/borderline serous tumor with cribriform features]
  - d. [Atypical proliferative /borderline seromucinous tumor (“mixed epithelial tumor”, “endocervical type mucinous tumor”)]
  - e. [Atypical proliferative/borderline mucinous tumor, gastrointestinal type]

- f. [Atypical proliferative/borderline endometrioid tumor]
  - g. [Atypical proliferative/borderline clear cell tumor]
  - h. [Atypical proliferative/borderline Brenner tumor]
  - i. [Low-grade serous carcinoma]
  - j. [High-grade serous carcinoma] (use of the term “papillary” is not recommended)
  - k. [Mucinous carcinoma, gastrointestinal type]
  - l. [Endometrioid carcinoma]
  - m. [Clear cell carcinoma]
  - n. [Malignant Brenner tumor]
  - o. [Transitional carcinoma]
  - p. [Undifferentiated carcinoma]
  - q. [Carcinosarcoma (malignant mixed Mullerian tumor, MMT)]
  - r. [Small cell carcinoma, hypercalcemic-type (“malignant rhabdoid tumor of the ovary”)]
  - s. [Mixed carcinoma <SPECIFY TYPES AND APPROXIMATE PERCENTAGES>]
  - t. [Adult-type granulosa cell tumor]
  - u. [Juvenile granulosa cell tumor]
  - v. [Sertoli-Leydig cell tumor]
  - w. [Sex cord tumor with annular tubules (SCTAT)]
  - x. [Steroid cell tumor, not-otherwise-specified]
  - y. [Other sex cord-stromal tumor <SPECIFY>]
  - z. [Dysgerminoma]
  - aa. [Embryonal carcinoma]
  - bb. [Yolk sac tumor]
  - cc. [Choriocarcinoma]
  - dd. [Immature teratoma]
  - ee. [Carcinoma ex teratoma]
  - ff. [Malignant mixed germ cell tumor <SPECIFY TYPES AND APPROXIMATE PERCENTAGES>]
  - gg. [Other, <SPECIFY>]
8. **Histologic Grade:** <SPECIFY GRADE OF TUMOR> (*grading system will depend on tumor type*)
9. **Ovarian Stromal Invasion:**
- a. [Absent]
  - b. [Present; microinvasion (< 0.5 cm)] (for use in borderline tumors)
  - c. [Present; > 0.5 cm] (for use in borderline tumors)
  - d. [Present] (for use in high-grade tumors where amount of stromal invasion doesn’t matter)
10. **Lymph-Vascular Space Invasion:** *state whether LVI is present*
- a. [Absent]
  - b. [Present]
  - c. [Suspicious]
  - d. [Cannot be determined]
11. **Ovarian Surface Involvement:** *specify whether there is surface involvement*

- a. [Absent]
  - b. [Present]
  - c. [Cannot be determined]
12. **Implants/Other Sites Involved:** *state whether there is disease outside the primary*
- a. [Negative]
  - b. [Positive: <LIST OTHER ORGANS INVOLVED> ; <PROVIDE SIZE OF LARGEST METASTATIC FOCUS>] (high-grade tumors)
  - c. [Non-invasive implants: <LIST NON-INVASIVE IMPLANT SITES>] (borderline and low-grade tumors)
  - d. [Invasive implants: <LIST INVASIVE IMPLANT SITES> ; <PROVIDE SIZE OF LARGEST METASTATIC FOCUS>] (borderline and low-grade tumors)
13. **Regional Lymph Nodes:** *provide lymph node status*
- a. [Not performed]
  - b. [Negative: 0 / <PROVIDE TOTAL LYMPH NODES>]
  - a. [Positive: <PROVIDE TOTAL NUMBER OF POSITIVE LYMPH NODES> / <PROVIDE TOTAL LYMPH NODES> ; <LIST SIZE OF LARGEST LYMPH NODE METASTASIS AND IF THERE IS EXTRANODAL EXTENSION>]
14. **Cytology:** *state whether or not cytology was performed and results, include accession number*
- a. [Not performed]
  - b. [Performed]:
    - i. [Positive, <PROVIDE ACCESSION NUMBER IF AVAILABLE>]
    - ii. [Negative, <PROVIDE ACCESSION NUMBER IF AVAILABLE>]
15. **Hormone Receptor Expression (by immunohistochemistry):** *provide ER and PR expression if applicable*
- a. [PENDING]
  - b. [ER: POSITIVE; <PROVIDE PERCENTAGE OF TUMOR CELLS STAINING AND STRENGTH OF STAINING>]
  - c. [ER: NEGATIVE]
  - d. [PR: POSITIVE; <PROVIDE PERCENTAGE OF TUMOR CELLS STAINING AND STRENGTH OF STAINING>]
  - e. [PR: NEGATIVE]
16. **Mismatch Repair (MMR) Protein Expression (by immunohistochemistry):** *provide MMR status if performed*
- a. [Not performed]
  - b. [<INPUT WHETHER STAINS ARE INTACT OR THERE IS LOSS OF EXPRESSION HOWEVER YOU WANT>]
17. **Pathologic Staging:** *may use AJCC and/or FIGO; refer to staging manuals*